Sequential Anti-PD1 Therapy Following Dendritic Cell Vaccination Improves Survival in a HER2 Mammary Carcinoma Model and Identifies a Critical Role for CD4 T Cells in Mediating the Response

Patients with metastatic HER2 breast cancer (MBC) often become resistant to HER 2 targeted therapy and have recurrence of disease. The Panacea trial suggested that HER2 MBC patients were more likely to respond to checkpoint therapy if TIL were present or if tumor expressed PD-L1. We assessed whether...

ver descrição completa

Na minha lista:
Detalhes bibliográficos
Publicado no:Front Immunol
Main Authors: Kodumudi, Krithika N., Ramamoorthi, Ganesan, Snyder, Colin, Basu, Amrita, Jia, Yongsheng, Awshah, Sabrina, Beyer, Amber P., Wiener, Doris, Lam, Lian, Zhang, Hongtao, Greene, Mark I., Costa, Ricardo L. B., Czerniecki, Brian J.
Formato: Artigo
Idioma:Inglês
Publicado em: Frontiers Media S.A. 2019
Assuntos:
Immunology
Acesso em linha:https://ncbi.nlm.nih.gov/pmc/articles/PMC6702967/
https://ncbi.nlm.nih.gov/pubmed/31475002
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.3389/fimmu.2019.01939
Tags: Adicionar Tag
Sem tags, seja o primeiro a adicionar uma tag!

Registos relacionados